In January 2022, Arterial Network conducted an exclusive interview with our company. Professor Wang Jianxun, the chief scientist, introduced the core team members and main service modules of Junhou Biotech. At present, Junhou Biology has built and put into production a 1000m2 GMP workshop, which is compared with other genetic engineering cellular immunotherapy projects2022年1月，動脈網(wǎng)對我司進行了專訪，首席科學家王建勛教授介紹了君厚生物的核心團隊成員及主要服務模塊。目前君厚生物已建成并投入生產(chǎn)1000m2 GMP級生產(chǎn)車間，相比于其他基因工程細胞免疫治療項目

With the scientific research still at the laboratory level, Junhou Biotech has been able to produce standardized clinical standards. Regarding the future market development and the company's prospects, Professor Wang Jianxun said that there is no mature benchmarking enterprise in China at present. Junhou Bio has more than three years of technology leadership and at least more than one generation of product generation leadership, and is expected to occupy more than 50% of the market in this field. Junhou Bio is equivalent to a water seller in the cell therapy industry, providing a steady stream of power for the middle and downstream companies trying to dig gold.仍停留在實驗室水平的科學研究，君厚生物已經(jīng)具備規(guī)范化的臨床級標準的生產(chǎn)能力。對于未來市場發(fā)展及公司前景，王建勛教授表示，目前國內(nèi)還沒有成熟的對標企業(yè)，君厚生物擁有3年以上的技術領先和至少1代以上的產(chǎn)品代差領先，預計能占領該領域50%以上的市場。君厚生物相當于細胞治療行業(yè)的賣水人，為試圖掘金的中下游公司提供了源源不斷的動力。